Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab

Basit Öğe Kaydı
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorErtugrul, Hamza
dc.contributor.authorFirat, Ugur
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorInal, Ali
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorPekkolay, Zafer
dc.date.accessioned2024-04-24T16:02:47Z
dc.date.available2024-04-24T16:02:47Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective The aim of this study was to assess whether trastuzumab usage is a risk factor for the development of brain metastasis (BM) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and factors affecting survival after development of BM. Materials and methods One hundred thirty-two patients treated with (treatment group) or without trastuzumab (control group) with brain metastasis were retrospectively analyzed. Results Ninety of the 132 HER2-positive MBC patients were in the treatment group and 42 were in the control group. BM was significantly increased in patients who were treated with trastuzumab in two or more lines (58.5 vs 24.1 %, p < 0.001). Trastuzumab and lapatinib usage after BM and age were independent prognostic factors for overall survival in univariate and multivariate analysis. Conclusion The risk for BM was increased in patients who were treated with trastuzumab in two or more lines. Using trastuzumab and lapatinib after BM and age were independent prognostic factors for time to death from BM.en_US
dc.identifier.doi10.1007/s12282-013-0513-z
dc.identifier.endpage509en_US
dc.identifier.issn1340-6868
dc.identifier.issn1880-4233
dc.identifier.issue5en_US
dc.identifier.pmid24385387
dc.identifier.scopus2-s2.0-84940960866
dc.identifier.scopusqualityQ1
dc.identifier.startpage503en_US
dc.identifier.urihttps://doi.org/10.1007/s12282-013-0513-z
dc.identifier.urihttps://hdl.handle.net/11468/14914
dc.identifier.volume22en_US
dc.identifier.wosWOS:000363722200009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofBreast Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBrain Metastasisen_US
dc.subjectTrastuzumaben_US
dc.titleBrain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumaben_US
dc.titleBrain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu